Cellectis S.A. (CMVLF)
USD 2.54
(0.0%)
USD 2.54
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 92.77 Million USD | 11.98% |
| 2022 | 82.84 Million USD | -18.97% |
| 2021 | 102.23 Million USD | -8.14% |
| 2020 | 111.29 Million USD | 133.78% |
| 2019 | 47.6 Million USD | 3423.83% |
| 2018 | 1.35 Million USD | 3873.53% |
| 2017 | 34 Thousand USD | -98.06% |
| 2016 | 1.75 Million USD | -19.2% |
| 2015 | 2.17 Million USD | -51.53% |
| 2014 | 4.48 Million USD | -20.17% |
| 2013 | 5.61 Million USD | -1.06% |
| 2012 | 5.67 Million USD | -91.79% |
| 2011 | 69.08 Million USD | 3694.27% |
| 2010 | 1.82 Million USD | -30.41% |
| 2009 | 2.61 Million USD | 44.12% |
| 2008 | 1.81 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 110.12 Million USD | 5.92% |
| 2024 Q1 | 103.96 Million USD | 12.06% |
| 2023 Q4 | 92.77 Million USD | 10.51% |
| 2023 FY | 92.77 Million USD | 11.98% |
| 2023 Q2 | 99.88 Million USD | 34.77% |
| 2023 Q3 | 83.95 Million USD | -15.95% |
| 2023 Q1 | 74.11 Million USD | -10.54% |
| 2022 Q4 | 82.84 Million USD | -14.27% |
| 2022 Q3 | 96.64 Million USD | 2.86% |
| 2022 FY | 82.84 Million USD | -18.97% |
| 2022 Q1 | 98.74 Million USD | -3.42% |
| 2022 Q2 | 93.95 Million USD | -4.85% |
| 2021 Q1 | 103.7 Million USD | -6.82% |
| 2021 Q4 | 102.23 Million USD | -1.02% |
| 2021 Q2 | 105.59 Million USD | 1.82% |
| 2021 Q3 | 103.28 Million USD | -2.18% |
| 2021 FY | 102.23 Million USD | -8.14% |
| 2020 Q1 | 50.04 Million USD | 5.11% |
| 2020 FY | 111.29 Million USD | 133.78% |
| 2020 Q3 | 103.16 Million USD | 37.03% |
| 2020 Q4 | 111.29 Million USD | 7.89% |
| 2020 Q2 | 75.28 Million USD | 50.44% |
| 2019 Q4 | 47.6 Million USD | 0.31% |
| 2019 Q2 | 47.81 Million USD | 34.13% |
| 2019 Q1 | 35.64 Million USD | 2538.64% |
| 2019 FY | 47.6 Million USD | 3423.83% |
| 2019 Q3 | 47.46 Million USD | -0.74% |
| 2018 Q3 | 486 Thousand USD | -51.55% |
| 2018 Q2 | 1 Million USD | 189.05% |
| 2018 Q1 | 347 Thousand USD | 920.59% |
| 2018 FY | 1.35 Million USD | 3873.53% |
| 2018 Q4 | 1.35 Million USD | 177.98% |
| 2017 Q4 | 34 Thousand USD | -26.09% |
| 2017 Q2 | 90.37 Thousand USD | -78.86% |
| 2017 Q1 | 427.44 Thousand USD | -75.65% |
| 2017 FY | 34 Thousand USD | -98.06% |
| 2017 Q3 | 46 Thousand USD | -49.1% |
| 2016 Q3 | 2.19 Million USD | -10.64% |
| 2016 FY | 1.75 Million USD | -19.2% |
| 2016 Q2 | 2.45 Million USD | 11.23% |
| 2016 Q4 | 1.75 Million USD | -20.13% |
| 2016 Q1 | 2.21 Million USD | 1.78% |
| 2015 Q3 | 3.43 Million USD | -1.9% |
| 2015 Q4 | 2.17 Million USD | -36.8% |
| 2015 Q2 | 3.5 Million USD | 517.73% |
| 2015 FY | 2.17 Million USD | -51.53% |
| 2015 Q1 | 567.22 Thousand USD | -87.35% |
| 2014 Q3 | 4.31 Million USD | -20.99% |
| 2014 Q4 | 4.48 Million USD | 3.84% |
| 2014 Q2 | 5.46 Million USD | 10.62% |
| 2014 Q1 | 4.93 Million USD | -12.05% |
| 2014 FY | 4.48 Million USD | -20.17% |
| 2013 Q2 | 1.26 Million USD | -74.56% |
| 2013 Q1 | 4.97 Million USD | -12.39% |
| 2013 Q4 | 5.61 Million USD | 17.68% |
| 2013 Q3 | 4.77 Million USD | 277.28% |
| 2013 FY | 5.61 Million USD | -1.06% |
| 2012 FY | 5.67 Million USD | -91.79% |
| 2012 Q2 | 5.49 Million USD | 0.0% |
| 2012 Q4 | 5.67 Million USD | 0.0% |
| 2011 FY | 69.08 Million USD | 3694.27% |
| 2011 Q4 | 69.08 Million USD | 0.0% |
| 2010 FY | 1.82 Million USD | -30.41% |
| 2010 Q4 | 1.82 Million USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | 2.61 Million USD | 44.12% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | 2.61 Million USD | 0.0% |
| 2008 Q4 | 1.81 Million USD | 0.0% |
| 2008 FY | 1.81 Million USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -125.169% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -2150.788% |
| SQZ Biotechnologies Company | 27.47 Million USD | -237.725% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -113.904% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -211.674% |
| Mesoblast Limited | 118.7 Million USD | 21.84% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -9683.755% |
| Genus plc | 233.1 Million USD | 60.199% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -3066.014% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -6805.151% |
| Marizyme, Inc. | 18.71 Million USD | -395.667% |
| ContraFect Corporation | 2.88 Million USD | -3120.288% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -12270.201% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -68376.317% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -6314.664% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -3888.749% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -1539.638% |
| MultiCell Technologies, Inc. | 202.58 USD | -45797366.68% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -61.381% |
| EV Biologics, Inc. | 1.49 Million USD | -6106.82% |
| Q BioMed Inc. | 4.1 Million USD | -2157.346% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -180.283% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -14624.63% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -7452.87% |
| Biomind Labs Inc. | 735.54 Thousand USD | -12513.353% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 45.917% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -613.83% |
| Skye Bioscience, Inc. | 4.61 Million USD | -1910.209% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -10347.052% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -65458.097% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -1480.226% |
| IMV Inc. | 28.88 Million USD | -221.205% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -360631.397% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -4008.098% |
| GB Sciences, Inc. | 1.75 Million USD | -5173.469% |
| Alpha Cognition Inc. | 1.22 Million USD | -7502.314% |
| HST Global, Inc. | 98.31 Thousand USD | -94262.746% |
| CSL Limited | 12.18 Billion USD | 99.238% |
| Halberd Corporation | 150 Thousand USD | -61751.005% |
| Enzolytics Inc. | 996.33 Thousand USD | -9211.75% |
| Resverlogix Corp. | 6.49 Million USD | -1329.31% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -19329.635% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -36198.674% |
| argenx SE | 20 Million USD | -363.883% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -103.636% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -3325.127% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -907249.711% |
| Genscript Biotech Corporation | 417.73 Million USD | 77.791% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -46145.817% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -3769.357% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -40362.342% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -37.156% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -2965.785% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -25692.029% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -356.398% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -62311.04% |
| BioStem Technologies, Inc. | 4.71 Million USD | -1869.185% |
| ONE Bio Corp. | 19.71 Million USD | -370.588% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -36983.606% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -37201.587% |
| Agentix Corp. | 50 Thousand USD | -185453.016% |
| LadRx Corporation | 33.6 Thousand USD | -275971.261% |
| Cell Source, Inc. | 9.25 Million USD | -902.537% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -12168.714% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -12168.714% |
| NovAccess Global Inc. | 2.19 Million USD | -4117.344% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1211.735% |
| Itoco Inc. | 228.37 Thousand USD | -40524.278% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -43875.119% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -1761.86% |
| Kadimastem Ltd | 891.22 Thousand USD | -10309.987% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -22987.405% |
| CytoDyn Inc. | 30.07 Million USD | -208.474% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -19057.459% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -26268.424% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1086.406% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -75635.925% |
| Rebus Holdings, Inc. | 310 Thousand USD | -29827.906% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -1859.26% |
| International Stem Cell Corporation | 4.17 Million USD | -2120.596% |
| Bioxytran, Inc. | 1.92 Million USD | -4719.559% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -148549.333% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -4154.047% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1015.639% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -980.682% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -5864.498% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -34518.1% |
| Neutra Corp. | 54.15 Thousand USD | -171213.443% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -4969.755% |
| PureTech Health plc | 25.51 Million USD | -263.658% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -7478.381% |
| IXICO plc | 472.02 Thousand USD | -19555.082% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -498.52% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -49.007% |
| CSL Limited | 12.18 Billion USD | 99.238% |